Intersect ENT Inc (NASDAQ:XENT) has received a consensus recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $36.50.
A number of research firms recently issued reports on XENT. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Wednesday, November 7th. BidaskClub raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Thursday, October 11th. Northland Securities reissued a “hold” rating and set a $28.00 target price on shares of Intersect ENT in a report on Wednesday, October 17th. Finally, ValuEngine raised shares of Intersect ENT from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd.
XENT stock opened at $29.43 on Thursday. The company has a market cap of $916.96 million, a P/E ratio of -52.55 and a beta of 0.58. Intersect ENT has a 1 year low of $25.15 and a 1 year high of $42.95.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Monday, November 5th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.02. The business had revenue of $24.70 million during the quarter, compared to analysts’ expectations of $24.09 million. Intersect ENT had a negative net margin of 20.00% and a negative return on equity of 17.62%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.15) EPS. Analysts anticipate that Intersect ENT will post -0.73 earnings per share for the current year.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $27.99, for a total transaction of $359,195.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $30.01, for a total transaction of $600,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 85,666 shares of company stock worth $2,505,926 over the last three months. Insiders own 5.90% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Intersect ENT by 3.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,377,070 shares of the medical equipment provider’s stock valued at $39,591,000 after purchasing an additional 50,060 shares during the last quarter. Morgan Stanley boosted its stake in shares of Intersect ENT by 126.1% in the 3rd quarter. Morgan Stanley now owns 234,650 shares of the medical equipment provider’s stock valued at $6,747,000 after purchasing an additional 130,847 shares during the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in shares of Intersect ENT in the 3rd quarter valued at $6,900,000. Teachers Advisors LLC boosted its stake in Intersect ENT by 15.7% during the third quarter. Teachers Advisors LLC now owns 367,132 shares of the medical equipment provider’s stock worth $10,555,000 after acquiring an additional 49,701 shares in the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Intersect ENT by 9.8% during the third quarter. Neuberger Berman Group LLC now owns 336,659 shares of the medical equipment provider’s stock worth $9,678,000 after acquiring an additional 30,029 shares in the last quarter. 91.66% of the stock is currently owned by hedge funds and other institutional investors.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Read More: How does inflation affect different investments?
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.